Parexel

Parexel is proud to partner with The Leukemia & Lymphoma Society in support of #LightTheNight 2024! As the "Shine Light on Patients" sponsor, we're committed to: ❤️ Supporting blood cancer patients and their families 💡 Funding critical clinical research for cures ✨ Shining a light on the darkness of cancer Last year after months of fundraising, Team Parexel made a fantastic showing at Light the Night walks in Cary, N.C. and Boston, Mass. This year, we're excited to do it all again! Join us in our global mission to advance therapies for blood cancer patients. Explore our team page: https://brnw.ch/21wLM8Y #LLS #BloodCancer #ClinicalResearch

AI brings significant advantages to clinical research, from drug discovery to patient recruitment and real-time data monitoring. This week, we spoke with Ed Fowler, Vice President, Operational Excellence, who shared his passion for how #AI is transforming the pharmaceutical industry. Ed's use of AI has allowed him to focus on more high-value activities on a day-to-day basis. Click through to read Ed's insights on the impact of AI in clinical research in the latest edition of our #AIandMe series. Share your experiences with AI in your work in the comments below! #ArtificialIntelligence #MachineLearning #DrugSafety

Navigate the complex world of regulatory affairs with confidence! Introducing the Regulatory Navigator series—explore the evolving regulatory landscape, gain actionable insights from Parexel experts, maximize success in clinical development, and accelerate patient access. Our regulatory experts share their breadth of experience to help you stay ahead of changes and optimize your clinical strategies. Subscribe now to receive the latest news and updates that can help streamline your path to market success! Learn more: https://lnkd.in/grXSU99g #Regulatory #PatientAccess #ParexelBiotech #ClinicalDevelopment

Parexel's 2023 ESG Report highlights our commitment to sustainability and its positive impact on patients, our industry and the planet. 🩺 🌍   As part of our climate initiatives, we introduced a first-class rail travel incentive in Germany to reduce air travel and environmental impact. This program increased train travel from 65% to 96% for trips under 4.5 hours, cutting air travel emissions by 30%! Read more in Business Travel News Europe: https://lnkd.in/eMC5t6kN

“In precision oncology, real-world evidence (RWE) must be a sustained strategy, not a tactical battle fought at product launch.” 🎯👏 In this edition of the New Medicines, Novel Insights newsletter, Emily Brouwer, VP, Epidemiology & Real-World Science at Parexel, explains how sponsors can deploy high-quality #RWE throughout the product lifecycle to optimize product planning, analyze the patient care pathway, de-risk development decisions, and drive market access. Learn why Emily believes RWE is the key to precision oncology 🔑 including five proven RWE strategies we have implemented to support sponsors. Read the full article below and subscribe to stay updated on the latest #NovelInsights #PrecisionOncology #Oncology #RealWorldEvidence #ClinicalTrials

🎙️ Looking for your next listen on your commute home? Tune in for insights from Parexel's Cris McDavid on the latest ACRO Good Clinical Podcast!   As Director of Global Clinical Operations for RBQM, Cris shares expertise on moving beyond the "belt and suspenders" approach in clinical data quality. Listen below for a sneak peek. 👇 👀   Don’t miss Cris and other industry experts as they analyze five years of RBM/RBQM adoption data and what it means for the future of clinical research. Access the full episode: https://lnkd.in/gdMz_agR #ClinicalResearch #RBQM #ACRO #GoodClinicalPodcast

Attention site partners, tomorrow is the last day to vote for the 2024 Society for Clinical Research Sites (SCRS) Eagle Award. Your vote is important to us, and we appreciate your partnership in driving meaningful change in clinical research. As an example of our commitment, check out the second episode of our "Enabling Successful Sites" series exploring how to better empower sites with the tools and training necessary to recruit diverse patient populations successfully. 💡 🎙️ This episode features an insightful discussion with: 🔹 Karen McIntyre, Vice President, Global Site Alliances 🔹 Xoli Belgrave, Senior Director, Head of Clinical Trial Diversity and Inclusion 🔹 Jamie Langley, Executive Director, Parexel Academy 🔹 Dr. Lovie Negrin, CEO and Founder of Randomize Now Tune in now and be part of the movement toward greater diversity, equity and inclusion in our industry! 🎧✨ https://lnkd.in/eXSbCSSd And don't forget to cast your vote here for the 2024 Eagle Award https://lnkd.in/eP6pKMp4 #ClinicalResearch #SitePartnerships #SuccessfulSites #EagleAward

FDA expedited designation trends are a marker of innovation, promise, and momentum in the R&D pipeline, particularly for cutting-edge therapies. 🆕📈 In this edition of the New Medicines, Novel Insights newsletter, Parexel’s Cell & Gene Therapy Center of Excellence explores the latest trends in FDA expedited development designations for advanced therapies regulated by the Center for Biologics Evaluation and Research (CBER), focusing on the three most recognizable regulatory designations available to innovative and novel products. Explore recent expedited development investigational products - and the supporting evidence used to attain these FDA designations. Read the full analysis and subscribe to receive the latest #NovelInsights from our thought leaders every week! #ParexelBiotech #FDA #CellTherapy #CBER

Parexel today announced the release of its 2023 Environmental, Social and Governance ("ESG") Report. The ESG Report is part of Parexel’s annual commitment to disclose and communicate the progress of its sustainability priorities, underscoring the company’s core values of putting Patients First and delivering With Heart™. "Our ESG progress in 2023 reflects our ongoing commitment to making a positive impact on the world around us by integrating sustainable, ethical practices into and across our business and our care for patients to transform the future of medicine,” - Peyton Howell, Chief Executive Officer. Click through for highlights of the company’s progress or access the press release and report here: https://lnkd.in/eeVMrbYA

This #DisabilityPrideMonth we celebrate the resilience, achievements and diversity of our colleagues in the disability community. 💪 More than 30 colleagues from around the globe serve on ParAbility, our Disability Steering Committee, sharing perspectives and providing leadership on issues impacting the disabled community. They help drive the actions Parexel can take as a company to become the model of inclusivity — in our industry and beyond. ParAbility is committed to: 🌈 Providing strategic recommendations aligned with organizational strategy, ensuring inclusivity at all levels. 🌈 Leading initiatives such as office accessibility audits, training programs and establishing feedback mechanisms for continuous improvement. 🌈 Emphasizing the importance of inclusive language and understanding diverse perspectives within the disability community. At Parexel, ParAbility is leading the way in fostering an accommodating workplace where everyone can thrive. #DisabilityPride #Inclusion #ProudToBeParexel